IGF1/IGFBP3 ratio revealed a tendency to decrease in patients with steatosis, confirmed by ultrasound and increased aminotransferases [111], as well as the ones with NAFLD and portal fibrosis [37]. The gene discussed is IGFBP3; the disease is metabolic dysfunction-associated steatotic liver disease.